Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to candida, aspergillus and rare molds. Patients undergoing chemotherapy and other immunosuppressive treatments end up with compromised immune systems. This makes them susceptible to a new disease—invasive fungal infections. Amplyx is advancing a novel small-molecule therapy, APX001, in clinical development. The Phase 1 program for APX001 is using both intravenous and oral formulations to address the need for treatment in both the hospital setting and continued convenient treatment after discharge.
San Diego, CA
© 2019 Pappas Capital, LLC. ALL RIGHTS RESERVED.